The 16th International Conference on Progress in Vaccination Against Cancer (PIVAC-16)


You must have javascript enabled on your browser to get the best out of this website and to request reports.

If you are unsure how to enable javascript in your browser, please consult the Help menu in your browser. This website may also be able to show you how to enable javascript:

12 – 14 September 2016
Winchester, UK


Progress in Vaccination Against Cancer (PIVAC) aims to bring together translational and clinical oncologists and immunologists dealing with active vaccination against cancer for three days of presentations on the most recent advances in the field. The meeting provides an up-to-date overview of many aspects of tumour immunology. Thanks to its friendly atmosphere and the limited number of participants, PIVAC cultivates lively and fruitful discussions, promotes interactions between participants, speakers and companies attending the conference and encourages the emergence of new partnerships.

99% of the participants from the 2015 edition of the meeting would recommend the conference to others

"It was a great opportunity to personally meet the most prominent researchers in the field of anti-cancer vaccination."

"Content and speakers are great, and the intimate size allows for easy communication with leaders in the field. Especially approachable for a student like myself."

"Several factors made the meeting outstanding. The smaller size allowed for extensive interactions with many attendees, and informal gatherings facilitated interactions."

Feedback from 2015 participants


The exploitation of the immune system to fight tumours has huge potential, but it still represents a challenge to be overcome. New information has been recently gathered on: the role of the tumour microenvironment as a major factor in determining the immunotherapy outcome; the exploitation of comparative oncology to predict immunotherapy effectiveness; and the potentialities of various vaccination strategies. Moreover, initial positive clinical results are becoming apparent. These new acquisitions will be the focus of PIVAC-16.

Who should attend?

PIVAC is dedicated to scientists working on active immunization against cancer, both in prevention and therapy, at the pre-clinical and/or clinical level. PIVAC is also an ideal environment to stimulate the interest of students and young researchers who approach this field of research.

Topics to be covered in the conference include:

  • Nucleic acid vaccines
  • Plant derived vaccines
  • Viral targeting of cancer
  • Phosphopetide targeting
  • Immunological adjuvancy through PI3K inhibition and chemotherapy
  • Immunostimulatory antibodies
  • Role of B-cells in solid cancers

We look forward to welcoming you to historic Winchester for this exciting conference!

Organising Committee Members
Christian Ottensmeier (Chair)
Robert C Rees, Sue Ostrand-Rosenberg, Per Thor Straten, Graham Pawelec, Natalia Savelyeva, Emma King

The conference is managed by the European Association for Cancer Research (EACR) on the behalf of the Organising Committee.